Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG

Malin K B Jonsson1, Marc A Vos, Gary R Mirams

  • 1Department of Medical Physiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands. m.k.b.jonsson@umcutrecht.nl

Insights

Human embryonic stem cell-derived cardiomyocytes (hESC-CM) show immature electrophysiology, limiting their use in safety pharmacology. Maturation is needed for accurate pro-arrhythmic trigger testing, except for hERG channel blockade.

Area of Science:

  • Cardiology
  • Stem Cell Biology
  • Pharmacology

Background:

  • Human embryonic stem cell-derived cardiomyocytes (hESC-CM) are a potential model for safety pharmacology.
  • Their electrophysiological properties and pro-arrhythmic potential require thorough investigation.

Purpose of the Study:

  • To evaluate the electrophysiology of hESC-CM.
  • To assess their response to pro-arrhythmic drug challenges.
  • To understand their suitability as a model for safety pharmacology.

Main Methods:

  • Voltage patch clamp to measure ion current densities.
  • Assessment of action potential parameters and early afterdepolarizations (EADs).
  • Computer simulations and AP clamp analysis.

Main Results:

  • hESC-CM exhibit specific ion current densities, with low I(K1) and larger I(f) compared to adult cardiomyocytes.
  • Chromanol293B and Bay K8644 prolonged APD(90); Cisapride triggered EADs.
  • Immature action potential in hESC-CM limits responses to pro-arrhythmic triggers, except for hERG block.

Conclusions:

  • hESC-CM possess an immature electrophysiological phenotype due to low I(K1) and shifted I(Na) channel activation.
  • This immaturity restricts their utility in safety pharmacology, particularly for non-hERG-related pro-arrhythmic triggers.
  • Electrical phenotype maturation is essential for implementing hESC-CM in arrhythmogenic safety testing.

Related Concept Videos